Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Novo Nordisk is emphasising that most patients taking CagriSema had mild-to-moderate side effects that were similar to Wegovy, with a more robust effect on weight loss and very low discontinuation ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Novo Nordisk reveals three new weight loss drugs, aiming to offer diverse options for obesity and weight management. ... CagriSema is, as the name hints, semaglutide but more ...

For Immediate Release Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog.

Det største danske pensionsselskab PFA havde ved udgangen af året en aktiepost i Novo Nordisk på 5.582 mio. kr., ifølge ...